Gilead Sciences (GILD) Non Operating Income (2009 - 2026)

Gilead Sciences has reported Non Operating Income for 18 years, with the latest figure at $235.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 171.65% year-over-year to $235.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 430.34% YoY), and the FY2025 full-year result was $798.0 million, up 13200.0% from the prior year.
• Non Operating Income for Q1 2026 stood at $235.0 million, down from $349.0 million in the prior quarter.
• The five-year high for Non Operating Income was $569.0 million in Q3 2025, with the low at -$355.0 million in Q2 2024.
• Historically, Non Operating Income has averaged $38.7 million across 5 years, with a median of -$10.0 million in 2022.
• Annual changes were most pronounced in 2023 — Non Operating Income surged 3030.0% — and 2025, when it tumbled 460.44%.
• Gilead Sciences' Non Operating Income stood at -$10.0 million in 2022, then surged by 3030.0% to $293.0 million in 2023, then plunged by 111.95% to -$35.0 million in 2024, then jumped by 1097.14% to $349.0 million in 2025, then slumped by 32.66% to $235.0 million in 2026.
• The last three Non Operating Income figures came in at $235.0 million (Q1 2026), $349.0 million (Q4 2025), and $569.0 million (Q3 2025), per Business Quant data.